It is important to mention that the 177Lu2O3-iPSMA nanoparticles developed in this research are not proposed as an option to replace prostate cancer therapies using ligands targeting PSMA, such as 177Lu-PSMA-617 or 177Lu-iPSMA [31,32]; what is proposed is the possibility of using 177Lu2O3-iPSMA for the treatment of liver metastases or tumors that express PSMA in the neovasculature, even with reduced or null expression of PSMA on the membrane of cancer cells. This evidence concerns the gene FOLH1 and prostate cancer.